Deuterated Ruxolitinib

Sun Pharmaceutical Industries has gained significant legal leverage after a US Court of Appeals vacated a preliminary injunction against its alopecia areata treatment Leqselvi, potentially enabling commercialization despite ongoing litigation with Incyte.

The U.S. Court of Appeals for the Federal Circuit has vacated a preliminary injunction against Sun Pharma, allowing the company to proceed with launching Leqselvi (deuruxolitinib) for alopecia areata in the American market.

Deuruxolitinib, an oral JAK1 and JAK2 inhibitor, has demonstrated significant efficacy in stimulating hair regrowth in adults with moderate to severe alopecia areata.

The Janus Kinase (JAK) inhibitor pipeline is actively being developed by multiple companies, showing promise in treating various autoimmune and inflammatory diseases.

A US district court in New Jersey has granted Incyte's preliminary injunction against Sun Pharma's Leqselvi (deuruxolitinib), halting its launch for alopecia areata treatment.